home / stock / opt / opt news

OPT News and Press, Opthea Limited

Stock Information
Company Name: Opthea Limited
Stock Symbol: OPT
Market: NASDAQ
Website: opthea.com
Menu
OPT OPT Quote OPT Short OPT News OPT Articles OPT Message Board
Get OPT Alerts

News, Short Squeeze, Breakout and More Instantly...
OPT - Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
OPT - Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer

New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approxima...

OPT - Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD

Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy MELBOURNE, Australia and PRINCETON, N.J....

OPT - Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1 ) will close at 5:00 pm (Melbourne time) on 10 July 2024 Prospectus and personalized application ...
OPT - Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1 ) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE, Australia and PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ...

OPT - Opthea announces placement, entitlement offer to raise up to $150M

2024-06-12 13:22:32 ET More on Opthea Seeking Alpha’s Quant Rating on Opthea Historical earnings data for Opthea Financial information for Opthea Read the full article on Seeking Alpha For further details see: Opthea announces placement, en...

OPT - Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2 calendar year 2025, and anticipated for ShORe in mid-calendar year 2025 MELBOURNE, Au...
OPT - Opthea To Present at Clinical Trials at the Summit Meeting

MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, inclu...

OPT - Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 (G...

OPT - Opthea Announces Upcoming Presentations at the Retina World Congress 2024

MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, includ...
Next 10